BofA analyst Jason Zemansky raised the firm’s price target on Insmed (INSM) to $211 from $209 and keeps a Buy rating on the shares. Though “absent much suspense” after the pre-announcement, BofA still thought Insmed’s earnings call was “solid” given several positive updates, including Brinsupri guidance for FY26 of at least $1B in sales, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- Insmed: Early Brinsupri Momentum but Policy Uncertainty and 2026 Pipeline Catalysts Justify Hold Rating
- Insmed price target lowered to $208 from $234 at Wells Fargo
- Brinsupri’s Breakout Growth, Robust Balance Sheet, and Upcoming Clinical Catalysts Underpin Buy Rating
- Insmed’s Brinsupri Launch Recasts Growth Outlook
- Insmed price target lowered to $205 from $212 at Stifel